The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Immunohistochemical expression of folate receptor α in colorectal carcinoma: patterns and biological significance
Abstract
Folate receptor alpha (FRalpha) has emerged as a potential cancer therapy target with several folate-linked therapeutic agents currently undergoing clinical trials. In addition, FRalpha expression in tumors may offer prognostic significance. Most studies on FRalpha expression used reverse transcriptase polymerase chain reaction or cytofluorimetric assays. The applicability of such methods to paraffin-embedded tissues is limited. The aims of this study were to assess the feasibility of immunohistochemistry in detecting FRalpha expression and to assess the patterns and clinical significance of FRalpha expression in colorectal tissues. We used tissue microarrays containing 152 normal colorectal mucosa samples, 42 adenomas, 177 primary, and 52 metastatic colorectal carcinomas. Our results showed that staining for FRalpha on colorectal tissues was simple and easy to read. FRalpha positivity was more frequent in carcinomas (33% in primaries and 44% in metastases) than in normal mucosa or adenoma (7% in both) (P < .001). Positive staining in primary carcinomas correlated with younger age (n = 130) (P = .008), presence of distant metastasis (n = 130) (P = .043), and non-high-frequency microsatellite instability status (as detected by the standard polymerase chain reaction method using the 5 National Cancer Institute-recommended markers) (n = 77) (P = .006). Positive staining in primary carcinomas also correlated with a worse 5-year disease-specific survival (P = .04) on univariate bu…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Folic acid is a receptor-selective targeting ligand that targets folic acid receptors overexpressed in many types of tumours including colorectal cancer.108”
From Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment (2022) · cites this paper as [108]
In the citing paper
“Moreover, peptide ligands show higher binding affinity and specificity with receptors compared to small molecule ligands.108,116”
From Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment (2022) · cites this paper as [108]
Citations
Cites
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Research works printed but not linked: 38
- Choi, 2000, Folate and carcinogenesis: an integrated scheme, J Nutr, 130, 129, 10.1093/jn/130.2.129 · DOI
- Antony, 1996, Folate receptors, Annu Rev Nutr, 16, 501, 10.1146/annurev.nu.16.070196.002441 · DOI
- Rijnboutt, 1996, Endocytosis of GPI-linked membrane folate receptor-alpha, J Cell Biol, 132, 35, 10.1083/jcb.132.1.35 · DOI
- Low, 2004, Folate receptor–targeted drugs for cancer and inflammatory diseases, Adv Drug Deliv Rev, 56, 1055, 10.1016/j.addr.2004.02.003 · DOI
- Lu, 2004, Folate receptor–targeted immunotherapy of cancer: mechanism and therapeutic potential, Adv Drug Deliv Rev, 56, 1161, 10.1016/j.addr.2004.01.009 · DOI
- Toffoli, 1997, Overexpression of folate binding protein in ovarian cancers, Int J Cancer, 74, 193, 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F · DOI
- Hartmann, 2007, Folate receptor overexpression is associated with poor outcome in breast cancer, Int J Cancer, 121, 938, 10.1002/ijc.22811 · DOI
- Parker, 2005, Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, Anal Biochem, 338, 284, 10.1016/j.ab.2004.12.026 · DOI
- Leamon, 2004, Folate-targeted chemotherapy, Adv Drug Deliv Rev, 56, 1127, 10.1016/j.addr.2004.01.008 · DOI
- Leamon, 2006, Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate, Bioconjug Chem, 17, 1226, 10.1021/bc060145g · DOI
- Hattori, 2005, Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase, Cancer Gene Ther, 12, 796, 10.1038/sj.cgt.7700844 · DOI
- Henne, 2006, Synthesis and activity of a folate peptide camptothecin prodrug, Bioorg Med Chem Lett, 16, 5350, 10.1016/j.bmcl.2006.07.076 · DOI
- Siegel, 2003, Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results, J Nucl Med, 44, 700
- Reddy, 2004, Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors, J Nucl Med, 45, 857
- Toffoli, 1998, Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer, Int J Cancer, 79, 121, 10.1002/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V · DOI
- Chang, 2007, Role of MTHFR polymorphisms and folate levels in different phenotypes of sporadic colorectal cancers, Int J Colorectal Dis, 22, 483, 10.1007/s00384-006-0190-x · DOI
- Choi, 2002, Folate status: effects on pathways of colorectal carcinogenesis, J Nutr, 132, 2413S, 10.1093/jn/132.8.2413S · DOI
- Kawakami, 2006, DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer, Br J Cancer, 94, 593, 10.1038/sj.bjc.6602940 · DOI
- Weitman, 1992, Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues, Cancer Res, 52, 3396
- Evans, 2003, Differential expression of folate receptor in pituitary adenomas, Cancer Res, 63, 4218
- Franklin, 1994, New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma, Int J Cancer Suppl, 8, 89, 10.1002/ijc.2910570719 · DOI
- Garin-Chesa, 1993, Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein, Am J Pathol, 142, 557
- Kononen, 1998, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nat Med, 4, 844, 10.1038/nm0798-844 · DOI
- Hoos, 2001, Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors, Am J Pathol, 158, 1245, 10.1016/S0002-9440(10)64075-8 · DOI
- Nash, 2003, Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer, J Clin Oncol, 21, 3105, 10.1200/JCO.2003.11.133 · DOI
- Shia, 2003, Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer, Am J Surg Pathol, 27, 1407, 10.1097/00000478-200311000-00002 · DOI
- Boland, 1998, A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res, 58, 5248
- Gonen, 2001, Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient, Radiology, 221, 763, 10.1148/radiol.2212010280 · DOI
- Reddy, 2006, Folate receptor specific anti-tumor activity of folate-mitomycin conjugates, Cancer Chemother Pharmacol, 58, 229, 10.1007/s00280-005-0151-z · DOI
- Cravo, 1992, Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine-treated rats, Cancer Res, 52, 5002
- Eaton, 2005, 5,10-Methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer, Cancer Epidemiol Biomarkers Prev, 14, 2023, 10.1158/1055-9965.EPI-05-0131 · DOI
- Kim, 2004, Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies, Environ Mol Mutagen, 44, 10, 10.1002/em.20025 · DOI
- de Vos tot Nederveen Cappel, 2004, Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer, Int J Cancer, 109, 468, 10.1002/ijc.11712 · DOI
- Ahuja, 1998, Aging and DNA methylation in colorectal mucosa and cancer, Cancer Res, 58, 5489
- Nakagawa, 2001, Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development, Cancer Res, 61, 6991
- Yuasa, 2002, DNA methylation in cancer and ageing, Mech Ageing Dev, 123, 1649, 10.1016/S0047-6374(02)00100-8 · DOI
- Toyota, 1999, CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci U S A, 96, 8681, 10.1073/pnas.96.15.8681 · DOI
- Feinberg, 2004, The epigenetics of cancer etiology, Semin Cancer Biol, 14, 427, 10.1016/j.semcancer.2004.06.005 · DOI
Cited by
Sorted by citations
Strategic approaches for colon targeted drug delivery: an overview of recent advancements
Lee, S. H., Bajracharya, R., Min, J. Y., Han, J.-W., Park, B. J., & Han, H.-K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010068 · Cited by 318
Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment
Choukaife, H., Seyam, S., Alallam, B., Doolaanea, A. A., & Alfatama, M. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s375229 · Cited by 127
Metadata
- Authors
- Shia, J., Klimstra, D. S., Nitzkorski, J. R., Low, P. S., Gonen, M., Landmann, R., Weiser, M. R., Franklin, W. A., Prendergast, F. G., Murphy, L., Tang, L. H., Temple, L., Guillem, J. G., Wong, W. D., & Paty, P. B.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 39
- Issue
- 4
- Pages
- 498-505
- ISSN
- 0046-8177
- Cited by
- 106
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review